Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma

  title={Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma},
  author={Bengt Simonsson and C K{\"a}llander and Gunilla Brenning and Andreas Killander and Anders {\AA}hre and J. Simon Gronowitz},
  journal={British Journal of Haematology},
Summary. A recently developed deoxythymidine kinase assay utilizing 125I‐iododeoxyuridine as substrate was used in an investigation of sera from 122 untreated patients with multiple myeloma. Most patients had slightly elevated or normal serum deoxythymidine kinase activity (S‐TK), although in some patients values increased by more than forty‐fold were found. S‐TK correlated with the haemoglobin level but did not correlate with sex, age, erythrocyte sedimentation rate, nor with the serum… 

Serum deoxythymidine kinase: no help in the diagnosis and prognosis of monoclonal gammopathy

Serum deoxythymidine kinase activity (S‐TK) was determined in the diagnostic evaluation and follow‐up of patients with monoclonal gammopathy of undetermined significance (MGUS) but does not give diagnostic or prognostic information in monoconal gamsopathy.

Serum deoxythymidine kinase as a progressive marker of hematological malignancy.

The results suggest that high levels of s-dTK in hematological malignancy may reflect the extent of disease and that this activity may be derived from proliferating leukemic cells.

Serum Thymidine Kinase and Beta-2 Microglobulin in Monoclonal Gammopathies

Serum TK as well as β-2 levels appear to be of clinical value in monoclonal gammopathies and related to the course of the disease.

Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma.

Detailed multiparameter longitudinal investigations of 5 patients and ongoing studies of 70 other patients suggest that STK is a more reliable marker of progressive disease than either SB2M, LI, M-protein or CD10 positive lymphocytes.

Serum thymidine kinase in monoclonal gammopathies. A prospective study

It is indicated that TK has clinical and prognostic relevance in monoclonal gammopathies, and additional investigations are warranted to determine whether it is a useful tool for the clinical evaluation, staging, and follow‐up of patients with MM.

Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia

When different variables and combinations of variables were studied in order to define their capacity for discriminating between progressive and indolent CLL, S‐TK activity and PI proved to be powerful indications.

Biochemical markers in multiple myeloma: a multivariate analysis

Summary. The analysis of individual biochemical and clinical variables in 121 patients with multiple myeloma showed that serum β2‐microglobulin (S‐β2m) had the most significant relation to survival.

Serum deoxythymidine kinase in myelodysplastic syndromes

This data indicates that serum levels of deoxythymidine kinase provide useful prognostic information in various malignancies, such as Hodgkin's disease, non‐Hodgkin's lymphomas, multiple myeloma, and acute myeloid leukemia.

Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC (UK) V Trial

STK is a good prognostic marker for patients treated with melphalan but the prognostic significance of STK may disappear with the introduction of new chemotherapy regimens.

Prognostic value of serum lactic dehydrogenase (S‐LDH) in multiple myeloma

Serum lactic dehydrogenase at diagnosis has prognostic information in multiple myeloma and in discriminant analysis of pretreatment S‐LDH levels in relation to survival, the best discrimination level was 7·0 μkat l‐1.



Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia

It is concluded that S‐TK could be used as a prognostic marker for the individual CLL patient and seems to be useful for longitudinal follow‐up studies of disease status, both in indolent disease and in progressive disease during treatment.

The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma.

It is concluded that s-dTk could be used both as a prognostic marker and to monitor the effect of therapy in NHL patients.

Application of an in vitro assay for serum thymidine kinase: Results on viral disease and malignancies in humans

The TK activity in sera from patients with both mononucleosis and tumor disease was characterized by electrophoresis and by its ability to utilize cytidine triphosphate as the phosphate donor, and showed that the serum TK has the same properties as the human cytosolar TK1, except in connection with varicella.

Serum thymidine kinase in acute leukaemia.

The development of a TK assay optimized for TK1, utilizing [1251] iododeoxyuridine as substrate, has been found to facilitate the detection of normal TK kinase activity.

Prognostic relevance of thymidine kinase isozymes in adult non-Hodgkin's lymphoma.

It is suggested that peripheral blood TK1 isozyme is a useful independent biochemical marker for a subgroup of NHL who respond poorly to current therapy and thus require new therapeutic approaches.

Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring.

Analysis of the influence of a rising serum creatinine on the serum beta 2-m indicates that beta 2 -m production is excessive in advanced disease with or without renal failure.

Deoxycytidine and deoxythymidine kinase activities in plasma of mice and patients with neoplastic disease.

In C57BL x DBA/2 F1 (hereafter called BD2F1) mice inoculated with P815 neoplasms and in AKR mice with spontaneously developing leukemia, significant amounts of plasma deoxycytidine and thymidine

Rapid diagnosis of varicella-zoster virus infection by detection of viral deoxythymidine kinase in serum and vesicle fluid

A sensitive enzyme assay utilizing [125I]iododeoxyuridine as the substrate and CTP as the phosphate donor in combination with isozyme-specific antisera was used for direct detection and typing of

Localized and indolent myeloma.

Serial assessments of myeloma protein level provided a useful index of changing tumor load and the need for chemotherapy and the delay of chemotherapy until evidence of tumor progression did not affect the long-term outcome of patients with localized or indolent Myeloma.

A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients.

The comparison of the duration of survival between the three groups of staged patients confirmed the high reliability of the present staging system, and bivariate correlation and multivariate regression analyses showed that the survival could be accurately predicted in IgG and pure Bence Jones myeloma patients.